CL2020003339A1 - Inhibidores de ectonucleotidasa y métodos de uso de los mismos - Google Patents
Inhibidores de ectonucleotidasa y métodos de uso de los mismosInfo
- Publication number
- CL2020003339A1 CL2020003339A1 CL2020003339A CL2020003339A CL2020003339A1 CL 2020003339 A1 CL2020003339 A1 CL 2020003339A1 CL 2020003339 A CL2020003339 A CL 2020003339A CL 2020003339 A CL2020003339 A CL 2020003339A CL 2020003339 A1 CL2020003339 A1 CL 2020003339A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- ectonucleotidase inhibitors
- ectonucleotidase
- inhibitors
- heterocyclic compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688225P | 2018-06-21 | 2018-06-21 | |
| US201962827505P | 2019-04-01 | 2019-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020003339A1 true CL2020003339A1 (es) | 2021-06-25 |
Family
ID=68981317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003339A CL2020003339A1 (es) | 2018-06-21 | 2020-12-21 | Inhibidores de ectonucleotidasa y métodos de uso de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11078228B2 (enExample) |
| EP (1) | EP3810617A4 (enExample) |
| JP (1) | JP7538047B2 (enExample) |
| KR (1) | KR102902754B1 (enExample) |
| CN (1) | CN112888696B (enExample) |
| AU (1) | AU2019288495B2 (enExample) |
| BR (1) | BR112020025132B1 (enExample) |
| CA (1) | CA3104088A1 (enExample) |
| CL (1) | CL2020003339A1 (enExample) |
| CO (1) | CO2021000049A2 (enExample) |
| IL (1) | IL279475B2 (enExample) |
| MX (1) | MX2020013320A (enExample) |
| PH (1) | PH12020552214A1 (enExample) |
| SG (1) | SG11202012001YA (enExample) |
| TW (1) | TWI911140B (enExample) |
| WO (1) | WO2019246403A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102638592B1 (ko) | 2016-12-22 | 2024-02-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 억제제 및 이의 용도 |
| US11129841B2 (en) | 2017-05-10 | 2021-09-28 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CA3098493A1 (en) | 2018-04-30 | 2019-11-07 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| KR102902754B1 (ko) * | 2018-06-21 | 2025-12-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 저해제 및 이의 사용 방법 |
| TWI821559B (zh) * | 2019-04-28 | 2023-11-11 | 大陸商上海和譽生物醫藥科技有限公司 | 一種cd73抑制劑，其製備方法和應用 |
| CA3143496A1 (en) * | 2019-06-20 | 2020-12-24 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN116854758A (zh) | 2019-10-30 | 2023-10-10 | 欧瑞克制药公司 | Cd73抑制剂 |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| CN116375772B (zh) * | 2023-02-13 | 2024-11-01 | 北京先通国际医药科技股份有限公司 | 腺苷的制备方法及其用途 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992019638A1 (en) | 1991-04-24 | 1992-11-12 | Yamasa Shoyu Kabushiki Kaisha | 1-β-D-ARABINOFURANOSYL-(E)-5-(2-HALOGENOVINYL)-URACIL DERIVATIVE |
| WO1994010128A1 (en) | 1992-11-02 | 1994-05-11 | Affymax Technologies N.V. | Novel photoreactive protecting groups |
| US5635608A (en) | 1994-11-08 | 1997-06-03 | Molecular Probes, Inc. | α-carboxy caged compounds |
| TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| NL1005244C2 (nl) | 1997-02-10 | 1998-08-18 | Inst Voor Agrotech Onderzoek | Oppervlakte-actieve aminen en glycosiden. |
| WO2004096233A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates |
| EP1860113A1 (en) | 2006-05-24 | 2007-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Ectonucleotidase inhibitors |
| EP2040712B1 (en) * | 2006-07-18 | 2011-03-02 | Anadys Pharmaceuticals, Inc. | Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines |
| WO2009061781A1 (en) | 2007-11-07 | 2009-05-14 | Schering Corporation | Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| EP2070938A1 (en) * | 2007-12-13 | 2009-06-17 | Heidelberg Pharma AG | Clofarabine dietherphospholipid derivatives |
| CA2684017A1 (en) | 2009-10-22 | 2011-04-22 | Universite Laval | Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1) as a target for the treatment of aortic valve stenosis and cardiovascular calcification |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| CN103209970B (zh) | 2010-07-08 | 2016-08-24 | 生命科技公司 | 原位化学发光底物和测定 |
| CN102311472B (zh) | 2010-07-09 | 2014-09-03 | 神隆(昆山)生化科技有限公司 | 2-氯-9-(2’-脱氧-2’-氟-β-D-阿拉伯呋喃糖基)-腺嘌呤的制备 |
| KR101960113B1 (ko) | 2011-05-03 | 2019-03-19 | 라이프 테크놀로지스 코포레이션 | 섬광 및 백열광 １,２-디옥세탄들 |
| EP3517539B1 (en) * | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
| GB201220843D0 (en) | 2012-11-20 | 2013-01-02 | Univ College Cork Nat Univ Ie | Compound |
| CN106463125B (zh) * | 2014-04-25 | 2020-09-15 | 杜比实验室特许公司 | 基于空间元数据的音频分割 |
| EP3134411B1 (en) | 2014-04-25 | 2021-06-30 | Boehringer Ingelheim International GmbH | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
| DK3362461T3 (da) | 2015-10-16 | 2022-05-09 | Modernatx Inc | Mrna-cap-analoger med modificeret phosphatbinding |
| WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
| US10611790B2 (en) | 2015-11-02 | 2020-04-07 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
| JP6411676B2 (ja) * | 2015-12-03 | 2018-10-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｓｔｉｎｇの調節因子としての環状プリンジヌクレオチド |
| CN110234656B (zh) | 2016-09-09 | 2023-02-28 | 卡利泰拉生物科技公司 | 外核苷酸酶抑制剂及其使用方法 |
| KR102638592B1 (ko) | 2016-12-22 | 2024-02-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 억제제 및 이의 용도 |
| US10794113B2 (en) * | 2016-12-22 | 2020-10-06 | Marketing Displays, Inc. | Compact privacy screen |
| WO2018208727A1 (en) * | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
| US11129841B2 (en) * | 2017-05-10 | 2021-09-28 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN109503587B (zh) * | 2017-09-14 | 2022-01-11 | 辽宁利锋科技开发有限公司 | 双杂环三氮唑核苷类似物的抗肿瘤作用与应用 |
| US11377469B2 (en) * | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CA3098493A1 (en) * | 2018-04-30 | 2019-11-07 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| TW202017569A (zh) * | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
| KR102902754B1 (ko) | 2018-06-21 | 2025-12-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 저해제 및 이의 사용 방법 |
| CA3143496A1 (en) | 2019-06-20 | 2020-12-24 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
-
2019
- 2019-06-20 KR KR1020217001701A patent/KR102902754B1/ko active Active
- 2019-06-20 WO PCT/US2019/038245 patent/WO2019246403A1/en not_active Ceased
- 2019-06-20 JP JP2020570902A patent/JP7538047B2/ja active Active
- 2019-06-20 CA CA3104088A patent/CA3104088A1/en active Pending
- 2019-06-20 US US16/447,159 patent/US11078228B2/en active Active
- 2019-06-20 MX MX2020013320A patent/MX2020013320A/es unknown
- 2019-06-20 CN CN201980054369.1A patent/CN112888696B/zh active Active
- 2019-06-20 IL IL279475A patent/IL279475B2/en unknown
- 2019-06-20 BR BR112020025132-1A patent/BR112020025132B1/pt active IP Right Grant
- 2019-06-20 EP EP19823042.7A patent/EP3810617A4/en active Pending
- 2019-06-20 SG SG11202012001YA patent/SG11202012001YA/en unknown
- 2019-06-20 AU AU2019288495A patent/AU2019288495B2/en active Active
- 2019-06-21 TW TW108121817A patent/TWI911140B/zh active
-
2020
- 2020-12-18 PH PH12020552214A patent/PH12020552214A1/en unknown
- 2020-12-21 CL CL2020003339A patent/CL2020003339A1/es unknown
-
2021
- 2021-01-06 CO CONC2021/0000049A patent/CO2021000049A2/es unknown
- 2021-06-28 US US17/359,990 patent/US11858957B2/en active Active
-
2023
- 2023-11-01 US US18/499,248 patent/US12421273B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020013320A (es) | 2021-02-22 |
| WO2019246403A1 (en) | 2019-12-26 |
| IL279475A (en) | 2021-01-31 |
| PH12020552214A1 (en) | 2021-08-16 |
| US20230022922A1 (en) | 2023-01-26 |
| BR112020025132A2 (pt) | 2021-03-23 |
| AU2019288495A1 (en) | 2021-01-28 |
| EP3810617A1 (en) | 2021-04-28 |
| KR102902754B1 (ko) | 2025-12-19 |
| EP3810617A4 (en) | 2022-06-29 |
| US11858957B2 (en) | 2024-01-02 |
| CO2021000049A2 (es) | 2021-04-19 |
| AU2019288495B2 (en) | 2024-02-08 |
| NZ771648A (en) | 2025-08-29 |
| US20240132533A1 (en) | 2024-04-25 |
| JP7538047B2 (ja) | 2024-08-21 |
| TWI911140B (zh) | 2026-01-11 |
| CN112888696B (zh) | 2024-04-16 |
| IL279475B1 (en) | 2025-09-01 |
| US12421273B2 (en) | 2025-09-23 |
| IL279475B2 (en) | 2026-01-01 |
| US11078228B2 (en) | 2021-08-03 |
| TW202010750A (zh) | 2020-03-16 |
| US20190389899A1 (en) | 2019-12-26 |
| KR20210024561A (ko) | 2021-03-05 |
| CA3104088A1 (en) | 2019-12-26 |
| BR112020025132B1 (pt) | 2023-10-10 |
| CN112888696A (zh) | 2021-06-01 |
| JP2021529172A (ja) | 2021-10-28 |
| SG11202012001YA (en) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021000049A2 (es) | Inhibidores de ectonucleotidasa y métodos de uso de los mismos | |
| MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| CO2021010312A2 (es) | Inhibidores de la pcsk9 y métodos de uso de los mismos | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2022014548A (es) | Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1). | |
| MX2022001940A (es) | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2. | |
| CO2018008761A2 (es) | Derivados de maitansinoide, conjugados de los mismos métodos de uso | |
| CL2022003046A1 (es) | Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| MX386103B (es) | Inhibidores de mcl-1 y metodos de uso de los mismos. | |
| MX2019011693A (es) | Compuestos que inhiben la proteina mcl-1. | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| CL2017003107A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| MX2018013387A (es) | Inhibidores de la arginasa y sus aplicaciones terapeuticas. | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. | |
| CL2021001198A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| MX2019014845A (es) | Compuestos de aminotiazol como inhibidores de la proteina quinasa. | |
| MX2019006843A (es) | Inhibidor de cdk4/6. | |
| UY37551A (es) | Activador de nrf2 | |
| MX2018013573A (es) | Ciertos inhibidores de la proteína cinasa. | |
| MX2021003888A (es) | Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares. |